179 related articles for article (PubMed ID: 28913549)
1. Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107.
Sato K; Kunisaki C; Kosaka T; Takagawa R; Takahashi M; Izumisawa Y; Miyamoto H; Sato S; Tanaka Y; Yamaguchi N; Kimura J; Ono HA; Makino H; Akiyama H; Endo I
Cancer Chemother Pharmacol; 2017 Nov; 80(5):939-943. PubMed ID: 28913549
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.
Kawakami H; Takeno A; Endo S; Makari Y; Kawada J; Taniguchi H; Tamura S; Sugimoto N; Kimura Y; Tamura T; Fujitani K; Sakai D; Shimokawa T; Kurokawa Y; Satoh T
Oncologist; 2018 Dec; 23(12):1411-e147. PubMed ID: 30115736
[TBL] [Abstract][Full Text] [Related]
3. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
[TBL] [Abstract][Full Text] [Related]
5. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
6. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
7. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H; Iwatsuki M; Uenosono Y; Shiraishi T; Tanioka H; Saeki H; Sugimachi K; Kitagawa D; Shimokawa M; Oki E; Emi Y; Kakeji Y; Tsuji A; Akagi Y; Natsugoe S; Baba H; Maehara Y;
Cancer Chemother Pharmacol; 2017 Jan; 79(1):147-153. PubMed ID: 27942930
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
14. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.
Kim YS; Sym SJ; Baek MY; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1267-72. PubMed ID: 26482716
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
17. Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H; Fujitani K; Matsuyama J; Akamaru Y; Tamura S; Endo S; Kimura Y; Makari Y; Tamura T; Sugimoto N; Sakai D; Tsujinaka T; Goto M; Kurokawa Y; Shimokawa T; Satoh T;
Int J Clin Oncol; 2020 Sep; 25(9):1635-1643. PubMed ID: 32494981
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Kang YK
Br J Cancer; 2016 May; 114(11):1185-90. PubMed ID: 27172248
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Salah-Eldin MA; Ebrahim MA; AL-Ashry MS
Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
